Клиническое исследование

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT: NCT04559685 · TERMINATED

NCT IDNCT04559685

СтатусTERMINATED

Дата начала2021-03-15

Завершение2024-11-10

SponsorNader Sanai (OTHER)

First posted2020-09-23

Last updated2026-05-14

Краткое описание

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.